LYRA
Lyra Therapeutics Inc
NASDAQ: LYRA · HEALTHCARE · BIOTECHNOLOGY
$0.71
+0.00% today
Updated 2026-04-30
Market cap
$870050.00
P/E ratio
—
P/S ratio
1.45x
EPS (TTM)
$-22.90
Dividend yield
—
52W range
$0 – $34
Volume
0.1M
Lyra Therapeutics Inc (LYRA) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | $25.36M | $14.96M | $80.83M | $54.87M | $109.97M | $142.60M | $66.35M |
| Cash & equivalents | $23.89M | $9.81M | $74.59M | $45.75M | $32.55M | $22.35M | $40.58M |
| Current assets | $24.93M | $10.12M | $75.92M | $47.92M | $100.83M | $104.82M | $43.02M |
| Total liabilities | $132.43M | $7.63M | $6.34M | $20.55M | $29.21M | $53.18M | $54.75M |
| Current liabilities | $1.96M | $5.21M | $4.88M | $18.25M | $14.47M | $19.60M | $12.63M |
| Long-term debt | — | — | — | — | — | — | — |
| Shareholder equity | $-107.07M | $7.33M | $74.49M | $34.32M | $80.75M | $89.42M | $11.59M |
| Retained earnings | $-111.45M | $-127.76M | $-149.88M | $-193.40M | $-248.68M | $-311.36M | $-404.79M |
| Accounts receivable | $167000.00 | — | — | — | — | — | — |
| Inventory | $1.00 | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — |